Velan Capital, L.P. 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Aug 27, 2019
Insider Transaction Report
Form 4
Velan Capital, L.P.
10% OwnerOther
Transactions
- Purchase
Common Stock, $0.0013 par value
2019-08-26$4.30/sh+73,230$314,911→ 7,418,672 total - Purchase
Common Stock, $0.0013 par value
2019-08-23$4.31/sh+130,826$563,690→ 7,345,442 total
Footnotes (2)
- [F1]This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 1(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
- [F2]Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital.